These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 6609009)
1. Quality control of biologicals produced by recombinant DNA techniques. WHO consultation. WHO Consultation Bull World Health Organ; 1983; 61(6):897-911. PubMed ID: 6609009 [TBL] [Abstract][Full Text] [Related]
2. The control of biological medicinal products produced by recombinant DNA technology. Griffiths E Dev Biol Stand; 1985; 59():155-9. PubMed ID: 4007273 [TBL] [Abstract][Full Text] [Related]
3. USDA licensing policy for biologicals produced by R-DNA. Espeseth DA; Shibley GP; Joseph PL; van Deusen RA; Whetstone CA Dev Biol Stand; 1985; 59():167-73. PubMed ID: 4007275 [TBL] [Abstract][Full Text] [Related]
4. Quality control of biologicals produced by r-DNA technology. Liu DT; Gates FT; Goldman ND Dev Biol Stand; 1985; 59():161-6. PubMed ID: 4007274 [TBL] [Abstract][Full Text] [Related]
5. Biologicals and vaccines: regulatory perspectives. Petricciani JC Dev Biol Stand; 1986; 63():15-9. PubMed ID: 3743903 [TBL] [Abstract][Full Text] [Related]
6. Ensuring the consistency of rDNA-derived biologicals: the contribution of gene sequencing. Griffiths E Dev Biol Stand; 1994; 83():179-82. PubMed ID: 7883093 [TBL] [Abstract][Full Text] [Related]
7. Specifications and quality control of a yeast-derived hepatitis B vaccine. Peetermans JH Postgrad Med J; 1987; 63 Suppl 2():97-100. PubMed ID: 3317364 [TBL] [Abstract][Full Text] [Related]
8. Control of recombinant DNA produced pharmaceuticals by a combination of process validation and final product specifications. Jones AJ; O'Connor JV Dev Biol Stand; 1985; 59():175-80. PubMed ID: 4007276 [TBL] [Abstract][Full Text] [Related]
10. Control of therapeutic goods produced by recombinant DNA technology. Breschkin A Dev Biol Stand; 1987; 67():207-11. PubMed ID: 3475226 [TBL] [Abstract][Full Text] [Related]
11. Successful development of recombinant DNA-derived pharmaceuticals. Werner RG; Pommer CH Arzneimittelforschung; 1990 Nov; 40(11):1274-83. PubMed ID: 2085342 [TBL] [Abstract][Full Text] [Related]
12. Quality assurance of products manufactured by recombinant DNA technology. Introduction and elements of a philosophy. van Noordwijk J Arzneimittelforschung; 1988 Jul; 38(7):943-7. PubMed ID: 3207439 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations. Report of the WHO Study Group on Cell Substrates for the Production of Biologicals, 22-23 April 2009, Bethesda, USA. Knezevic I; Stacey G; Petricciani J; Sheets R; Biologicals; 2010 Jan; 38(1):162-9. PubMed ID: 19818645 [TBL] [Abstract][Full Text] [Related]
14. Advanced process monitoring: the ultimate alternative. Neeleman R; Beuvery C Dev Biol (Basel); 2002; 111():273-82. PubMed ID: 12678250 [TBL] [Abstract][Full Text] [Related]
15. Three Rs potential in the development and quality control of immunobiologicals. Halder M ALTEX; 2001; 18 Suppl 1():13-47. PubMed ID: 11854853 [TBL] [Abstract][Full Text] [Related]
16. A 4R concept for the safety testing of immunobiologicals. Cussler K Dev Biol Stand; 1999; 101():121-6. PubMed ID: 10566784 [TBL] [Abstract][Full Text] [Related]
17. Gene stability in mammalian cells and protein consistency. Berthold W Dev Biol Stand; 1994; 83():67-79. PubMed ID: 7883100 [TBL] [Abstract][Full Text] [Related]
19. Supplement to the points to consider in the production and testing of new drugs and biologicals produced by recombinant DNA technology: nucleic acid characterization and genetic stability. Biologicals; 1993 Mar; 21(1):81-3. PubMed ID: 8217122 [No Abstract] [Full Text] [Related]
20. Genetic stability and product consistency of rDNA-derived biologicals from mammalian cells. Bebbington CR; Lambert K Dev Biol Stand; 1994; 83():183-4. PubMed ID: 7883094 [No Abstract] [Full Text] [Related] [Next] [New Search]